FDA Approves Pembrolizumab Combo for Advanced or Recurrent Endometrial Cancer
FDA approves pembrolizumab + carboplatin/paclitaxel for advanced/recurrent endometrial cancer based on KEYNOTE-868 phase 3 trial data.
FDA Approves Pembrolizumab Combo for Advanced or Recurrent Endometrial Cancer Read More ยป